NTLA · Healthcare
Intellia Therapeutics Inc
28/100
Smart-money confidence1 of 3 sources positive
Weak — few signals
No standout activity across the feeds we track.
Hedge funds
38
Congress
No data
Insiders
No data
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. ·
how the score works
Market cap
$1.7B
Industry
Biotechnology
Sector
Healthcare
Exchange
NasdaqGM
About INTELLIA THERAPEUTICS INC
Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated 9 (Cas9) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company's in vivo product candidates include nexiguran ziclumeran, or NTLA-2001 for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary…
Who's behind the signal
Every informed buyer we can see on NTLA, across all three feeds.
Hedge funds · 7
Point72 (Steve Cohen)
New position
ARK Invest (Cathie Wood)
Increased +2%
D.E. Shaw & Co
Increased +7%
AQR Capital Management
Increased +101%
Tudor Investment (Paul Tudor Jones)
Decreased −53%
Citadel Advisors
Decreased −52%
+1 more in the full breakdown below ↓
Congress · 0
No congressional trades on record.
Insiders
No significant Form 4 insider activity in the window.
Congressional trades · 12 on record
Disclosures from 2017-10-19 to 2022-02-28
The newest disclosure we hold for this stock is 2022-02-28.
That is the end of our data, not necessarily the end of the trading — our
bulk STOCK Act archive stops there and newer filings arrive through a
separate live feed. Treat the absence of recent rows as “not covered”,
not as “no trades”.
| Trade date | Member | Chamber | Action | Amount |
|---|---|---|---|---|
| 2022-02-28 | Donald S. Beyer, Jr. · D-VA | House | Sold | $15,001 - $50,000 |
| 2021-10-29 | Donald S. Beyer, Jr. · D-VA | House | Sold | $1,001 - $15,000 |
| 2021-09-20 | Donald S. Beyer, Jr. · D-VA | House | Sold | $1,001 - $15,000 |
| 2021-07-21 | Donald S. Beyer, Jr. · D-VA | House | Sold | $1,001 - $15,000 |
| 2021-01-15 | Donald S. Beyer, Jr. · D-VA | House | Sold | $1,001 - $15,000 |
| 2020-11-20 | Thomas R. Carper · D-DE | Senate | Bought | $1,001 - $15,000 |
| 2020-11-18 | Donald S. Beyer, Jr. · D-VA | House | Bought | $1,001 - $15,000 |
| 2020-08-26 | Donald S. Beyer, Jr. · D-VA | House | Sold | $1,001 - $15,000 |
| 2020-07-10 | Donald S. Beyer, Jr. · D-VA | House | Bought | $1,001 - $15,000 |
| 2020-01-14 | Donald S. Beyer, Jr. · D-VA | House | Bought | $1,001 - $15,000 |
Show the other 2
| Trade date | Member | Chamber | Action | Amount |
|---|---|---|---|---|
| 2018-10-25 | James M. Inhofe · R-OK | Senate | Sold | $15,001 - $50,000 |
| 2017-10-19 | James M. Inhofe · R-OK | Senate | Bought | $15,001 - $50,000 |
Not a model pick — but on our radar.
INTELLIA THERAPEUTICS INC isn't in the top-10 model right now, but 7 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
7
Investors
1
New positions
3
Increasing
3
Decreasing
0
Unchanged
Price History
Loading price data...
Return:
High:
Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Trust weight: 1.1×
% of portfolio
0.0%
Position change
NEW
0.0% of Point72's portfolio
Trust weight: 1.3×
% of portfolio
1.4%
Position change
+2%
1.4% of ARK Invest's portfolio
Trust weight: 1.0×
% of portfolio
0.1%
Position change
+7%
0.1% of D.E. Shaw & Co's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
+101%
0.0% of AQR Capital Management's portfolio
Trust weight: 1.2×
% of portfolio
0.0%
Position change
−53%
0.0% of Tudor Investment's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
−52%
0.0% of Citadel Advisors's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
−44%
0.0% of Millennium Management's portfolio
Portfolio Allocation
How much of each investor's portfolio is allocated to INTELLIA THERAPEUTICS INC
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell INTELLIA THERAPEUTICS INC or any security.
订阅每周更新
我们每周会把巴菲特、达利欧、阿克曼以及另外 47 位传奇投资人正在买入的股票发送给你 — 免费，直接来自他们的 SEC 申报文件。
永久免费 · 无垃圾邮件 · 随时退订